---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030372"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:13:05.578055+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q2 2024 revenue up 5.4% to $1.74M; net loss widens; positive CGuard trial data

## Summary
- Q2 2024 revenue $1.74M (+5.4% YoY); gross margin fell to 19.0% from 29.8% on higher costs.
- Net loss $7.9M ($0.22/share) vs $5.1M ($0.24) YoY; operating expenses up 48% to $8.6M.
- CGuard stent sales 2,969 units; one-year C-GUARDIANS trial primary endpoint rate 1.95% (lowest ever).
- Raised $17.9M gross from full exercise of Series H warrants; cash & equivalents $47.2M at June 30.
- Intends to submit PMA application to FDA this quarter; plans CGUARDIANS II TCAR trial in H2 2024.

## SEC filing metadata
- accession: 0001493152-24-030372
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/0001493152-24-030372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030372
- JSON: https://secwatch.observer/filing/0001493152-24-030372.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.